Literature DB >> 22044658

Pulmonary complications of pneumococcal community-acquired pneumonia: incidence, predictors, and outcomes.

C Cillóniz1, S Ewig, E Polverino, C Muñoz-Almagro, F Marco, A Gabarrús, R Menéndez, J Mensa, A Torres.   

Abstract

The aim of this study was to evaluate the clinical characteristics, predictors and outcomes of pneumococcal pneumonia developing pulmonary complications and the distribution of pneumococcal serotypes. It was a prospective study including all adult patients admitted to the Hospital Clinic of Barcelona, Spain (2001-2009) with the diagnosis of pneumococcal pneumonia. Microbiological investigation was systematically performed, including antimicrobial susceptibility and serotype distribution (only invasive strains isolated during 2006-2009). Complicated pneumonia was defined as the presence of one or more pulmonary complications: pleural effusion, empyema, or multilobar infiltrates. We included 626 patients, and 235 (38%) had the following pulmonary complications: pleural effusion, 122 (52%); empyema, 18 (8%); and multilobar infiltration, 151 (64%). Forty-six (20%) patients had more than one complication. Patients with pulmonary complications showed a higher rate of intensive-care unit admission (34% vs. 13%, p <0.001), a higher rate of shock (16% vs. 7%, p <0.001), a longer length of stay (9 days vs. 6 days, p <0.001), and a lower rate of penicillin resistance (14% vs. 25%, p 0.013), but similar mortality (9% vs. 8%). No significant differences were observed in the serotype distribution between complicated and uncomplicated pneumonia. Chronic obstructive pulmonary disease (COPD) (OR 0.38, 95% CI 0.23-0.63; p <0.001) was a protective factor against pulmonary complications, whereas chronic liver disease (OR 3.60, 95% CI 1.71-7.60; p 0.001), admission C-reactive protein level ≥18 mg/dL (OR 2.77, 95% CI 1.91-4.00; p <0.001) and admission creatinine level >1.5 mg/dL (OR 2.01, 95% CI 1.31-3.08; p 0.001) were risk factors for pulmonary complications. Complicated pneumonia was characterized by a more severe clinical presentation, but was not associated with increased mortality. Resistance to antibiotics was lower in complicated cases. No significant differences were observed in the serotype distribution between complicated and uncomplicated pneumonia. In the multivariate analysis, COPD was a protective factor against pulmonary complications.
© 2011 The Authors. Clinical Microbiology and Infection © 2011 European Society of Clinical Microbiology and Infectious Diseases.

Entities:  

Mesh:

Year:  2011        PMID: 22044658     DOI: 10.1111/j.1469-0691.2011.03692.x

Source DB:  PubMed          Journal:  Clin Microbiol Infect        ISSN: 1198-743X            Impact factor:   8.067


  13 in total

1.  Lung abscess complicating pneumococcal pneumonia: a causal role of non-steroidal anti-inflammatory drugs?

Authors:  Aude Gibelin; Nicolas de Prost; Christian Brun-Buisson
Journal:  BMJ Case Rep       Date:  2013-08-20

2.  Allergic Lung Inflammation Reduces Tissue Invasion and Enhances Survival from Pulmonary Pneumococcal Infection in Mice, Which Correlates with Increased Expression of Transforming Growth Factor β1 and SiglecF(low) Alveolar Macrophages.

Authors:  Alan M Sanfilippo; Yoichi Furuya; Sean Roberts; Sharon L Salmon; Dennis W Metzger
Journal:  Infect Immun       Date:  2015-05-11       Impact factor: 3.441

3.  Risk factors for pneumococcal endocarditis.

Authors:  T J Marrie; G J Tyrrell; S R Majumdar; D T Eurich
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2017-10-24       Impact factor: 3.267

4.  Burden of pneumococcal disease among adults in Southern Europe (Spain, Portugal, Italy, and Greece): a systematic review and meta-analysis.

Authors:  Adoración Navarro-Torné; Eva Agostina Montuori; Vasiliki Kossyvaki; Cristina Méndez
Journal:  Hum Vaccin Immunother       Date:  2021-06-09       Impact factor: 4.526

Review 5.  Pneumococcal empyema and complicated pneumonias: global trends in incidence, prevalence, and serotype epidemiology.

Authors:  M A Fletcher; H-J Schmitt; M Syrochkina; G Sylvester
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2014-02-23       Impact factor: 3.267

6.  Twenty-year trend in mortality among hospitalized patients with pneumococcal community-acquired pneumonia.

Authors:  Catia Cillóniz; Adamantia Liapikou; Ignacio Martin-Loeches; Carolina García-Vidal; Albert Gabarrús; Adrian Ceccato; Daniel Magdaleno; Josep Mensa; Francesc Marco; Antoni Torres
Journal:  PLoS One       Date:  2018-07-18       Impact factor: 3.240

7.  The relevance of pneumococcal serotypes.

Authors:  Chamira Rodrigo; Wei Shen Lim
Journal:  Curr Infect Dis Rep       Date:  2014-04       Impact factor: 3.725

Review 8.  Clinical implications of pneumococcal serotypes: invasive disease potential, clinical presentations, and antibiotic resistance.

Authors:  Joon Young Song; Moon H Nahm; M Allen Moseley
Journal:  J Korean Med Sci       Date:  2013-01-08       Impact factor: 2.153

Review 9.  Risk factors for community-acquired pneumonia in adults in Europe: a literature review.

Authors:  Antoni Torres; Willy E Peetermans; Giovanni Viegi; Francesco Blasi
Journal:  Thorax       Date:  2013-11       Impact factor: 9.139

Review 10.  The aetiology and antibiotic management of community-acquired pneumonia in adults in Europe: a literature review.

Authors:  A Torres; F Blasi; W E Peetermans; G Viegi; T Welte
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2014-02-15       Impact factor: 3.267

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.